For research use only. Not for therapeutic Use.
IN04(CAT: I029292) is a novel inhibitor of leucine-rich repeat kinase 1 (LRRK1), specifically designed to suppress osteoclast function without affecting osteoclast differentiation. By targeting LRRK1, IN04 disrupts key signaling pathways involved in osteoclast activity, reducing bone resorption while preserving normal osteoclast formation. This selective mechanism makes IN04 a valuable tool in bone and metabolic research, particularly for studying diseases like osteoporosis and other conditions associated with excessive bone loss. Its specificity for LRRK1 provides a promising avenue for developing targeted therapies to maintain bone health while minimizing off-target effects.
| Catalog Number | I029292 |
| Synonyms | IN04; IN-04; IN 04 |
| Molecular Formula | C20H19N3O6S |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | Methyl 3-(2-((5-(3,5-dimethoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)acetamido)benzoate |
| InChI | InChI=1S/C20H19N3O6S/c1-26-15-8-13(9-16(10-15)27-2)18-22-23-20(29-18)30-11-17(24)21-14-6-4-5-12(7-14)19(25)28-3/h4-10H,11H2,1-3H3,(H,21,24) |
| InChIKey | MCQJCSNFOKHYLJ-UHFFFAOYSA-N |
| SMILES | O=C(OC)C1=CC=CC(NC(CSC2=NN=C(C3=CC(OC)=CC(OC)=C3)O2)=O)=C1 |
